Creative Medical Health Granted U.S. Patent for Heart Failure Stem Cell Therapy

Clinical Stage Regenerative Medicine Company Expands Intellectual Property Portfolio

PHOENIX--()--Creative Medical Health Inc. announced today issuance of U.S. Patent #9,205,112, titled “Combination Therapy of Cardiovascular Disease” by the United States Patent and Trademark Office. The patent covers the use of adult stem cells such as cord blood and mesenchymal stem cells in combination with modulation of oxidative stress in treatment of heart failure. Additionally, the patent covers in-treatment assessment of oxidative stress so as to give doctors ability to personalize the treatment protocol to the particular needs of the patient.

“The issuance of the current patent places Creative Medical Health in a unique position in that it covers not only unique stem cell combinations, but also means of specifically tailoring treatment to the needs of each patient; something that to my knowledge does not exist anywhere else.”

"Stem cell therapy is a clinical reality, with several treatments approved by regulatory authorities around the world. We are moving to the next level of stem cell therapy, where patient-specific treatments and manipulation of the conditions in which stem cells are implanted are becoming critical,” said Dr. Amit N. Patel, Director of the Regenerative Medicine and Tissue Engineering in the Department of Surgery at the University of Utah, and founding Board Member of Creative Medical Health. “The issuance of the current patent places Creative Medical Health in a unique position in that it covers not only unique stem cell combinations, but also means of specifically tailoring treatment to the needs of each patient; something that to my knowledge does not exist anywhere else.”

The patent is based on animal and clinical data, demonstrating that manipulation of oxidative stress potently synergies with cord blood and mesenchymal stem cells to greatly augment regenerative effects of stem cells after administration.

“I am greatly enthusiastic that years of research that went into the development of the science behind this new approach to heart failure have now culminated into issuance of a U.S. patent,” said Thomas Ichim, Ph.D., Founding Board Member of Creative Medical Health and Senior Vice President. “In my opinion, the current patent not only protects the products that we are developing in-house, but also the patent will need to be licensed by others who are seeking to optimize existing stem cell therapies.”

Publications by independent groups, subsequent to priority date of the patent, as well as clinical observations, have supported the fact that stem cells function best in environments of low oxidative stress. The current patent discloses methods of modulating oxidative stress in order to optimize effects of stem cell therapy; therefore, it is applicable to a variety of different adult stem cell products that are on the market or on the way to entering the market.

“Creative Medical Health has previously demonstrated its ability to rapidly translate patented regenerative medicine products from bench to bedside, as witnessed by our currently ongoing clinical trial in using stem cells for treatment of erectile dysfunction, which is the subject of our issued patent #8,372,797. We are highly optimistic for clinical advancement of the current patent, either internally or through licensing partners,” said Timothy Warbington, CEO and Chairman of Creative Medical Health.

For further information about Creative Medical Health, Inc. please visit our website at creativemedicalhealth.com.

Contacts

Creative Medical Health Inc.
Timothy Warbington, 602-680-7439
ceo@creativemedicalhealth.com